Thus, using antagonists that would limit MDM2 action represents a valuable anti-cancer approach, independently of the TP53 status of cancer cells (Toledo and Wahl, 2006; Bohlman and Manfredi, 2014, 2016). Here, TP53 is linked to cancer.